Cargando…
Tuberculosis innovations mean little if they cannot save lives
The past decade has seen the emergence of new diagnostics and drugs for tuberculosis, a disease that kills over 1.8 million people each year. However, these new tools are yet to reach scale, and access remains a major challenge for patients in low and middle income countries. Urgent action is needed...
Autores principales: | Pai, Madhukar, Furin, Jennifer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5413344/ https://www.ncbi.nlm.nih.gov/pubmed/28460659 http://dx.doi.org/10.7554/eLife.25956 |
Ejemplares similares
-
Lives saved with vaccination for 10 pathogens across 112 countries in a pre-COVID-19 world
por: Toor, Jaspreet, et al.
Publicado: (2021) -
Standardized mean differences cause funnel plot distortion in publication bias assessments
por: Zwetsloot, Peter-Paul, et al.
Publicado: (2017) -
Risk factors relate to the variability of health outcomes as well as the mean: A GAMLSS tutorial
por: Bann, David, et al.
Publicado: (2022) -
Previously undetected super-spreading of Mycobacterium tuberculosis revealed by deep sequencing
por: Lee, Robyn S, et al.
Publicado: (2020) -
In-host population dynamics of Mycobacterium tuberculosis complex during active disease
por: Vargas, Roger, et al.
Publicado: (2021)